Next Steps in Bladder Cancer to Include Combination Immunotherapy – OncLive
OncLive |
Next Steps in Bladder Cancer to Include Combination Immunotherapy
OncLive While the 5 PD-1/PD-L1 inhibitors approved by the FDA in a 2-year span have drastically shifted the therapeutic paradigm of bladder cancer, researchers are already taking next steps that include combination regimens to have a greater benefit across … |
